Conforti F, Bagnardi V, Sala I. Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer". J Clin Oncol 2025 Jul 2:JCO2501041. doi: 10.1200/JCO-25-01041.
PMID: 40601891